Oculatax (Latanoprost)

Oculatax is a prostaglandin analog that reduces intra‑ocular pressure in glaucoma‑related conditions.

• Open‑angle glaucoma: lowers intra‑ocular pressure to help prevent optic‑nerve damage.
• Ocular hypertension: reduces eye pressure to lower the risk of developing glaucoma.
• Secondary glaucoma: assists in controlling pressure when other causes elevate intra‑ocular tension.

• Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the ciliary body, increasing uveoscleral outflow of aqueous humor. This enhanced outflow reduces intra‑ocular pressure, helping to protect the optic nerve from pressure‑related damage.

Adverse reactions to latanoprost are generally mild to moderate and may affect the eye or surrounding tissues.

Common Side Effects

• Eye redness: mild hyperemia of the conjunctiva.
• Eyelash changes: increased length, thickness, or darkening.
• Periocular skin darkening: hyperpigmentation of the eyelid skin.
• Eye irritation: stinging or burning sensation on instillation.
• Blurred vision: transient visual disturbance after dosing.

Serious or Rare Side Effects

• Iridocyclitis: inflammation of the iris and ciliary body.
• Corneal edema: swelling of the cornea that may affect vision.
• Persistent ocular pain: ongoing discomfort not relieved by typical measures.
• Severe allergic reaction: signs include swelling, rash, or difficulty breathing.
• Vision loss: sudden decrease in visual acuity requiring immediate medical attention.

When using Oculatax, patients and clinicians should consider several safety measures.

• Monitor intra‑ocular pressure: regular eye‑pressure checks are essential.
• Assess for ocular infections: avoid use if active eye infection is present.
• Caution in patients with a history of uveitis: may increase risk of inflammation.
• Avoid concurrent use with other prostaglandin analogues: may amplify side‑effects.
• Store at below 25°C: keep in the original container, protect from light and moisture.

Latanet is 

Major Interactions (Avoid)

• Concomitant use with non‑steroidal 

-          ... -  ...  Moderate  g  g  t  t  t""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""